123 related articles for article (PubMed ID: 30776753)
21. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
Sawada N; Nomiya M; Hood B; Koslov D; Zarifpour M; Andersson KE
Eur Urol; 2013 Oct; 64(4):664-71. PubMed ID: 23838637
[TBL] [Abstract][Full Text] [Related]
22. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.
Chapple C; Khullar V; Nitti VW; Frankel J; Herschorn S; Kaper M; Blauwet MB; Siddiqui E
Eur Urol; 2015 Jan; 67(1):11-14. PubMed ID: 25092537
[TBL] [Abstract][Full Text] [Related]
24. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
[TBL] [Abstract][Full Text] [Related]
25. Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β
Yamaguchi O; Ikeda Y; Ohkawa S
Low Urin Tract Symptoms; 2017 Jan; 9(1):38-45. PubMed ID: 28120446
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
[TBL] [Abstract][Full Text] [Related]
27. Profile of mirabegron in the treatment of overactive bladder: place in therapy.
Sharaf A; Hashim H
Drug Des Devel Ther; 2017; 11():463-467. PubMed ID: 28255232
[TBL] [Abstract][Full Text] [Related]
28. Mirabegron, a β
Mendes-Silvério CB; Alexandre EM; Lescano CH; Antunes E; Mónica FZ
Eur J Pharmacol; 2018 Jun; 829():79-84. PubMed ID: 29654782
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.
Rosa GM; Ferrero S; Nitti VW; Wagg A; Saleem T; Chapple CR
Eur Urol; 2016 Feb; 69(2):311-23. PubMed ID: 26422675
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of a sensitive LC-MS/MS assay for simultaneous quantitation of ranolazine and its three metabolites in human plasma.
Wang Y; Chen X; Sun Z; Yang Y; Zhang Y; Liu W; Zhong D
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 889-890():10-6. PubMed ID: 22377406
[TBL] [Abstract][Full Text] [Related]
32. Cryo-EM structure of the β3-adrenergic receptor reveals the molecular basis of subtype selectivity.
Nagiri C; Kobayashi K; Tomita A; Kato M; Kobayashi K; Yamashita K; Nishizawa T; Inoue A; Shihoya W; Nureki O
Mol Cell; 2021 Aug; 81(15):3205-3215.e5. PubMed ID: 34314699
[TBL] [Abstract][Full Text] [Related]
33. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
Tyagi P; Tyagi V
IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594
[TBL] [Abstract][Full Text] [Related]
34. The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.
Svalø J; Nordling J; Bouchelouche K; Andersson KE; Korstanje C; Bouchelouche P
Eur J Pharmacol; 2013 Jan; 699(1-3):101-5. PubMed ID: 23246623
[TBL] [Abstract][Full Text] [Related]
35. Mirabegron: β3-adrenergic receptor agonist for the treatment of overactive bladder.
Bridgeman MB; Friia NJ; Taft C; Shah M
Ann Pharmacother; 2013; 47(7-8):1029-38. PubMed ID: 23757386
[TBL] [Abstract][Full Text] [Related]
36. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Miyashita A; Iwatsubo T; Usui T
Xenobiotica; 2012 Dec; 42(12):1187-96. PubMed ID: 22834478
[TBL] [Abstract][Full Text] [Related]
37. Validation of an LC-MS/MS method for the quantitative determination of the orexin receptor antagonist almorexant and its four primary metabolites in human plasma.
Wagner-Redeker W; Finsterwald I; Dingemanse J
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Mar; 951-952():96-103. PubMed ID: 24531213
[TBL] [Abstract][Full Text] [Related]
38. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
Nozawa Y; Kato D; Tabuchi H; Kuroishi K
Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
[TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).
Torimoto K; Matsushita C; Yamada A; Goto D; Matsumoto Y; Hosokawa Y; Miyake M; Aoki K; Hirayama A; Tanaka N; Fujimoto K
Neurourol Urodyn; 2017 Apr; 36(4):1097-1103. PubMed ID: 27265880
[TBL] [Abstract][Full Text] [Related]
40. Off-line solid phase extraction and liquid chromatography-tandem mass spectrometry method for the quantitation of brivaracetam acid metabolites: Method validation and application to in vitro metabolism assays.
Bourgogne E; Culot B; Dell'Aiera S; Chanteux H; Stockis A; Nicolas JM
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1086():138-145. PubMed ID: 29665472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
